The introduction of fentanyl on the US–Mexico border: An ethnographic account triangulated with drug checking data from Tijuana

Abstract

Background

Illicitly-manufactured fentanyls (fentanyl) have changed the risk environment of people who use drugs (PWUD). In California and many western US states, the opioid overdose rate spiked from 2016 to 2021, driven largely by fentanyl. Mexican border cities act as transit through-points for the illicit drug supply and similar evolving health risks are likely to be present. Nevertheless, due to data gaps in surveillance infrastructure, little is known about fentanyl prevalence in Mexico.

Methods

We employ intensive ethnographic participant-observation among PWUD, as well as key informants including harm reduction professionals, EMTs, and physicians on the front lines in Tijuana, Mexico. We triangulate interview data and direct observations of consumption practices with n=652 immunoassay-based fentanyl tests of drug paraphernalia from mobile harm reduction clinics in various points throughout the city.

Results

PWUD informants described a sharp increase in the psychoactive potency and availability of powder heroin—referred to as “china white”—and concomitant increases in frequency of overdose, soft tissue infection, and polysubstance methamphetamine use. Fentanyl positivity was found among 52.8% (95%CI: 48.9–56.6%) of syringes collected at harm reduction spaces, and varied strongly across sites, from 2.7% (0.0–5.7%) to 76.5% (68.2–84.7%), implying strong market heterogeneity. Controlling for location of collection, syringe-based fentanyl positivity increased by 21.7% (10.1–42.3%) during eight months of testing. Key informants confirm numerous increased public health risks from fentanyl and describe the absence of a systematic or evidence-based governmental response; naloxone remains difficult to access and recent austerity measures have cut funding for harm reduction in Mexico.

Conclusions

Fentanyl, linked to powder heroin, is changing the risk environment of PWUD on the US–Mexico border. Improved surveillance is needed to track the evolving street drug supply in Mexico and related health impacts for vulnerable populations. Structural factors limiting access to naloxone, harm reduction, substance use treatment, and healthcare, and minimal overdose surveillance, must be improved to provide an effective systemic response.

Introduction

The evolving street drug supply is fundamentally changing the risk environment for people who use drugs (PWUD) (Ciccarone, 2017; Beletsky & Davis, 2017; Brinkley-Rubinstein et al., 2018; Lambdin et al., 2019; Shover et al., 2020; Ciccarone, 2021), understood as the space, both at an individual and societal level, where factors interact to increase the harm of substance use (Rhodes, 2002). In particular, the rise of illicitly-manufactured-fentanyls (hereafter fentanyl) is of urgent concern as it is driving steeply rising overdose rates and other health risks for PWUD in North America. Fentanyl is a family of synthetic opioid agonists many times stronger than heroin. Sold in pure form, mixed with heroin, erroneously sold as heroin itself, or, increasingly pressed into pills (especially imitating oxycodone and benzodiazepines), fentanyl is increasingly present in the illicit opioid supply (Ciccarone, 2017; Ciccarone, 2021). The increasing volatility of the drug supply—where presence or concentration of fentanyl are not known by consumers—is implicated in the worst overdose crisis seen in the United States to date, which claimed nearly 600,000 lives in the decade ending in 2020 (Friedman & Akre, 2021).

Fentanyl's transformative power in the risk environment reflects its pharmacological properties and their behavioral implications. When compared to non-synthetic opioids, fentanyls have a shorter half-life, but higher potency. This necessitates more frequent injection, as analgesia and euphoria wane, and withdrawal symptoms present more quickly (Mayer et al., 2018). Increased injection occurrence has been hypothesized to elevate the risk of myriad deleterious health outcomes, such as overdose, soft-tissue infection, and the transmission of infectious diseases such as HIV and Hepatitis C (Lambdin et al., 2019; Bobashev et al., 2019).

Drug market shifts have both local importance, and international implications, given the global nature of the drug supply. In the United States, the prevalence of fentanyl was initially heavily concentrated in Eastern US states (Ciccarone, 2017; Shover et al., 2020). However, in recent years it has begun moving Westward, including proximate to the US–Mexico border (Shover et al., 2020). According to the US Drug Enforcement Agency, the vast majority of the opioid supply in the US originates from Mexican drug trafficking organizations (Ciccarone, 2017; Drug Enforcement Administration, 2020).

Other than relatively isolated populations of PWUD in the country's largest cities, opioid injecting occurs almost exclusively along Mexico's northern border (Goodman-Meza et al., 2018; Bucardo et al., 2005). In this context, fentanyl is likely to be having similarly transformative effects on the risk environment for PWUD in Mexico, to those recently seen in California and other US border states (Friedman & Akre, 2021). Further, given that Mexican border cities act as transit through-points for the US illicit drug supply, fentanyl surveillance in US–Mexican border cities could provide early evidence about shifts that will subsequently occur in the US. Nevertheless, there is a dearth of drug surveillance data in Mexico, largely stemming from structural limitations on epidemiological and drug checking data streams. Toxicological and autopsy data is extremely limited in Mexico (West et al., 2020), and most overdose deaths are coded with so-called ‘garbage codes’ such as ‘cardiac arrest’ which are not informative as to the true underlying cause of mortality (West et al., 2020; Híjar et al., 2012). A previous study in three border cities in Mexico found a near absence of self-reported fentanyl use among PWUD, although individuals may be unaware of the composition of substances purchased on illicit and unregulated markets (Fleiz, 2019). A prior study in Tijuana tested a convenience sample of n=89 syringes and additional components of injection equipment, and noted the presence of fentanyl (Fleiz et al., 2020). Given limitations of the existing data, we draw on complementary methodologies to describe the shifting drug supply and risk environment for PWUD on the US–Mexico border.